An Electronic Chart Intervention to Improve Safety for Patients on Chronic Opioid Therapy
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Chronic Opioid Therapy
- Sponsor
- Stanford University
- Enrollment
- 43
- Locations
- 1
- Primary Endpoint
- Change in the number of patients who receives naloxone prescription
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
This pilot study will attempt to apply an electronic chart intervention to improve safety for patients on chronic opioid medications.
Investigators
Huiqiong Deng
Clinical Assistant Professor
Stanford University
Eligibility Criteria
Inclusion Criteria
- •Patients prescribed long-term opioid therapy of doses greater than 90 morphine equivalent daily dose (MEDD)
Exclusion Criteria
- •Patients prescribed short-term opioid medications for acute pain (less than a 90-day supply over the past 120 days), sublingual buprenorphine, methadone maintenance for opioid use disorder or with oncology or palliative care diagnoses will be excluded.
Outcomes
Primary Outcomes
Change in the number of patients who receives naloxone prescription
Time Frame: baseline, 1, 3- and 6-months and 12 months
Change in the number of patients who receives naloxone prescription
change of number of documentation about safety discussions
Time Frame: baseline, 1, 3- and 6-months and 12 months
change of number of documentation about safety discussions
change of number of order for urine toxicology screening
Time Frame: baseline, 1, 3- and 6-months and 12 months
change of number of order for urine toxicology screening
change of number of documentation of prescription drug monitoring program (CURES) results
Time Frame: baseline, 1, 3- and 6-months and 12 months
change of number of documentation of prescription drug monitoring program (CURES) results
change of number of signed opioid informed consent forms
Time Frame: baseline, 1, 3- and 6-months and 12 months
change of number of signed opioid informed consent forms
Secondary Outcomes
- Change in number of patients on long-term high risk doses of opioid pain medications(baseline, 1, 3- and 6-months and 12 months)